Showing 2491-2500 of 5623 results for "".
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Focus Vitamins Unveils New Blue Light Product to Help Protect Eyes from Digital Devices and Eye Fatiguehttps://modernod.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/Covalent Medical, owner of the brand “Focus Vitamins,” announced today that their new Blue Light mango-flavored gummy will be available to their partner physician practices for resale. “The B.L.U.E. study shows using electronic digital devices can cause eye fatigue, and even interrupt slee
- Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/Ocugen and Bharat Biotech announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Under th
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Designhttps://modernod.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/Aldeyra Therapeutics announced the finalization of the design of the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry
- GSK, CureVac Partner to Develop mRNA Vaccines for COVID-19 Variantshttps://modernod.com/news/gsk-curevac-partner-to-develop-mrna-vaccines-for-covid-19-variants/2478831/GlaxoSmithKline entered into a new collaboration with CureVac to develop a multi-valent mRNA candidate vaccine to address multiple emerging variants of COVID-19, the companies announced Wednesday. “We believe that next-generation vaccines will be crucial in the continued fight against COVID
- Jazz to Buy Cannabinoid Drugmaker GW Pharma in $7.2-Billion Dealhttps://modernod.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/Jazz Pharmaceuticals entered into a definitive agreement to acquire GW Pharmaceuticals for $220 per share, or a total consideration of $7.2 billion, adding the latter’s cannabinoid product platform, including Epidiolex (cannabidiol), to its neuroscience pipeline, the companies announced Wed
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery Systemhttps://modernod.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/Alcon has announced a nationwide launch of the Clareon IOL with the AutonoMe delivery system in Canada. AutonoMe is an automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the capsular bag in patients undergoing cataract surgery, according to